UPDATE: The MIRA FOA for early stage investigators has been reissued.
We have begun making grant awards resulting from responses to RFA-GM-16-003 (R35), the Maximizing Investigators’ Research Award (MIRA) for New and Early Stage Investigators pilot program. We received 320 applications in areas related to NIGMS’ mission, and they were reviewed by four special emphasis panels organized by the NIH Center for Scientific Review. We anticipate making 93 awards, which is more than we estimated in the funding opportunity announcement (FOA); the corresponding success rate is 29.1%.
The awards will be for a 5-year project period, as is typically the case for NIGMS R01 awards to new and early stage investigators. Most awards will be for the requested and maximum amount of $250,000 in annual direct costs, with an average of $239,000 and median of $250,000. In Fiscal Year 2015, NIGMS R01 awards to new or early stage investigators averaged $209,000 in annual direct costs (median of $198,000) and had a 24.4% success rate. During the same period, all competing NIGMS R01 awards averaged $236,000 in annual direct costs (median of $210,000) and had a 28.8% success rate. Thus, the MIRA pilot program had success rates similar to those of comparable R01 applications and offered some direct financial benefit to this group of applicants. We expect other benefits of the MIRA program, including increased funding stability and research flexibility, reductions in time spent writing and reviewing grant applications and improved distribution of NIGMS funding, will accrue among these investigators and the community at large as implementation of the MIRA program continues.
You can find more information about the awards on NIH RePORTER by entering RFA-GM-16-003 in the FOA field; however, the record of funded grants will not be complete until after the end of Fiscal Year 2016 (September 30). Because the initial budget period of MIRA awards will be offset by existing NIGMS grant support from other mechanisms (e.g., career awards), the first-year budget of a MIRA may be lower than the annual funding level used to calculate the average and median amounts shown above. We plan to post a detailed analysis of MIRAs after we have issued all the awards. We’ve previously posted information on NIGMS R01 award sizes and success rates for new and early stage investigators.
As I mentioned in my last post, we’re planning to reissue the MIRA FOA for early stage investigators in the near future.
You can find additional information about the program on our MIRA web page.
We have published median and mean direct cost award amounts for R01 grants, but these statistical aggregates can mask variations present in our grant portfolio. In this analysis, we illuminate two major differences in R01 award size distributions: those between single-principal investigator (PI) and multiple-PI (MPI) grants and those between new and competing renewal grants. It is worth noting that the numbers are per award values rather than the total NIGMS support provided to investigators and that award size can also be influenced by NIH-wide policies and NIGMS-specific policies that promote the consideration of multiple factors in making funding decisions.
The first major distinction in NIGMS R01s exists between single-PI and MPI awards. NIH has allowed applications that identify more than one PI since Fiscal Year 2007. Many MPI applications request, and receive, larger amounts of funding than do typical single-PI applications. As shown in Figure 1, single-PI awards have a size peak in the range of $175,000-200,000 in direct costs (funds typically directly associated with the research project rather than overhead costs), while MPI awards tend to have larger budgets and a broader size distribution. MPI awards are, on average, approximately 25% larger for each additional PI (data not shown).
Continue reading “Distribution of NIGMS R01 Award Sizes”
As part of our program assessment process, we have analyzed NIGMS program project (P01) grants to improve our understanding of how their outcomes compare with those of other mechanisms.
The most recent NIGMS funding opportunity announcement for P01s states that individual projects “must be clearly interrelated and synergistic so that the research ideas, efforts, and outcomes of the program as a whole will offer a distinct advantage over pursuing the individual projects separately.” From this perspective, we sought to address three major questions:
- Do P01s achieve synergies above and beyond a collection of separate grants?
- How do the results from P01s compare with those from R01s?
- Do certain fields of science need P01s more than others?
To address these questions, we analyzed the outcomes of P01 grants using several different metrics and compared these outcomes to those of two comparator groups: single-principal investigator (PI) R01s and multiple-PI R01s. Since P01s could be considered as a collection of single-PI R01s and one or more cores, we chose single-PI R01s as a comparator group. Because a major facet of P01s is their focus on using collaborative approaches to science, we also wanted to compare their outcomes to another collaboration-focused research grant: multiple-PI R01s. While structurally different from P01s, multiple-PI R01s allow for a comparison between two competing models of funding team science within the NIGMS portfolio.
Continue reading “P01 Outcomes Analysis”
We have begun making grant awards resulting from responses to RFA-GM-16-002 (R35), the Maximizing Investigators’ Research Award (MIRA) pilot program. Out of the 179 applications we received, we have so far authorized 123 awards. The median yearly direct costs for these grants is $399,842, and the mean is $405,884. For comparison, the median yearly direct costs for an NIGMS R01 in Fiscal Year 2015 was $210,000, and the mean was $237,254. On average, the budgets of these MIRAs to established investigators were reduced by 12% relative to the investigators’ recent NIGMS funding history. As described in the funding opportunity announcement (FOA), the budget reductions were in exchange for the benefits of the program: a 5-year award instead of the standard 4-year one, increased flexibility to follow new research directions, increased funding stability and decreased administrative burden. We will use the funds freed up through this trade-off to support other investigators and improve the distribution of NIGMS funding. It will take time for the full benefits of the program to individual investigators and the research community to become clear.
You can find more information about these awards on NIH RePORTER by entering RFA-GM-16-002 in the FOA field; however, the record of funded grants will not be complete until the end of Fiscal Year 2016. Because merging an investigator’s previous funding into a single award presents a variety of complications, in some cases the first-year budget of the MIRA is lower than the eventual funding level will be. This is frequently the case when the principal investigator (PI) was part of multi-PI grants that will be allowed to end before all NIGMS funding for the investigator is put on the MIRA or when the PI had already received funds from NIGMS in the current fiscal year.
We will begin making awards for the new and early stage investigators MIRA (RFA-GM-16-003) after the May 19-20 meeting of the National Advisory General Medical Sciences Council.
You can find additional information about the program on our MIRA web page.